Guard Therapeutics International AB (GUARD) - Cash Flow Conversion Efficiency

Latest as of September 2025: -1.630x

Based on the latest financial reports, Guard Therapeutics International AB (GUARD) has a cash flow conversion efficiency ratio of -1.630x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-90.70 Million ≈ $-9.76 Million USD) by net assets (Skr55.63 Million ≈ $5.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GUARD cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Guard Therapeutics International AB - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Guard Therapeutics International AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Guard Therapeutics International AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guard Therapeutics International AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
CryptoStar Corp V:CSTR	-0.160x
Health and Plant Protein Group Ltd AU:HPP	-0.067x
Searchlight Resources Inc V:SCLT	-0.141x
Prestal Holdings Ltd AU:PTL	-0.192x
ICZOOM Group Inc. Class A Ordinary Shares NASDAQ:IZM	0.083x
Libas Consumer Products Limited NSE:LIBAS	0.001x
Marula Mining PLC F:48U0	N/A
Mynaric AG XETRA:M0YN	0.271x

Annual Cash Flow Conversion Efficiency for Guard Therapeutics International AB (2012–2024)

The table below shows the annual cash flow conversion efficiency of Guard Therapeutics International AB from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Guard Therapeutics International AB stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr37.97 Million ≈ $4.09 Million	Skr-94.75 Million ≈ $-10.20 Million	-2.496x	-43.52%
2023-12-31	Skr66.73 Million ≈ $7.18 Million	Skr-116.05 Million ≈ $-12.49 Million	-1.739x	-201.96%
2022-12-31	Skr177.36 Million ≈ $19.09 Million	Skr-102.14 Million ≈ $-10.99 Million	-0.576x	-30.46%
2021-12-31	Skr175.78 Million ≈ $18.92 Million	Skr-77.59 Million ≈ $-8.35 Million	-0.441x	+7.34%
2020-12-31	Skr79.69 Million ≈ $8.58 Million	Skr-37.96 Million ≈ $-4.09 Million	-0.476x	+58.36%
2019-12-31	Skr52.62 Million ≈ $5.66 Million	Skr-60.21 Million ≈ $-6.48 Million	-1.144x	-105.75%
2018-12-31	Skr-2.94 Million ≈ $-316.28K	Skr-58.46 Million ≈ $-6.29 Million	19.890x	+1063.17%
2017-12-31	Skr31.96 Million ≈ $3.44 Million	Skr-66.01 Million ≈ $-7.10 Million	-2.065x	-33.35%
2016-12-31	Skr30.34 Million ≈ $3.26 Million	Skr-46.98 Million ≈ $-5.06 Million	-1.549x	-123.61%
2015-12-31	Skr42.69 Million ≈ $4.59 Million	Skr-29.56 Million ≈ $-3.18 Million	-0.693x	-427.08%
2014-12-31	Skr52.25 Million ≈ $5.62 Million	Skr-6.87 Million ≈ $-738.89K	-0.131x	-18.18%
2013-12-31	Skr25.42 Million ≈ $2.74 Million	Skr-2.83 Million ≈ $-304.12K	-0.111x	-134.81%
2012-12-31	Skr30.58 Million ≈ $3.29 Million	Skr-1.45 Million ≈ $-155.83K	-0.047x	--

About Guard Therapeutics International AB

ST:GUARD Sweden Biotechnology

Market Cap

$3.37 Million

Skr31.30 Million SEK

Market Cap Rank

#29267 Global

#666 in Sweden

Share Price

Skr1.55

Change (1 day)

+2.11%

52-Week Range

Skr0.95 - Skr25.90

All Time High

Skr3260.75